Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders

• Main Authors: Kotaro Sakamoto (Author), Lu Chen (Author), Tatsunori Miyaoka (Author), Mei Yamada (Author), Teruaki Masutani (Author), Kenji Ishimoto (Author), Nobumasa Hino (Author), Shinsaku Nakagawa (Author), Satoshi Asano (Author), Yukio Ago (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Worldwide, more than 20 million people suffer from schizophrenia, but effective and definitive new therapeutic drugs/treatments have not been established. Vasoactive intestinal peptide receptor 2 (VIPR2) might be an attractive drug target for the treatment of schizophrenia because both preclinical a...